Sector News

Bristol-Myers, Pfizer and Eisai bet big biobucks on the Japanese market

February 3, 2016
Life sciences

Bristol-Myers Squibb, Pfizer and Eisai are targeting Japan’s growing pharma market with a pair of deals in the cardiovascular and oncology spaces, signing back-loaded agreements to push new drugs in the country.

Bristol-Myers and Pfizer, makers of the blood thinner Eliquis, inked a deal with Portola Pharmaceuticals to develop and launch the company’s reversal agent in Japan. Portola’s andexanet alfa, submitted for FDA approval in December, is an antidote to so-called Factor Xa inhibitors like Eliquis and Xarelto. Bristol-Myers and Pfizer are paying $15 million up front for the Japanese rights to the treatment, promising another $20 million tied to approval and up to $70 million more if Portola’s therapy meets its sales goals.

And Eisai, in a separate deal, has partnered with China’s Huya Bioscience on an investigational treatment for blood cancer. Eisai is handing over an undisclosed up-front payment and signing on to pay as much as $270 million more in exchange for the rights to HBI-8000 in Japan, South Korea, Thailand, Malaysia, Indonesia, the Philippines, Vietnam and Singapore. The drug is an oral treatment that targets enzymes called HDACs, which play a role in regulating the growth of tumor cells. Huya’s treatment is in development as a treatment for lymphoma and solid tumors, Eisai said.

For Bristol-Myers and Pfizer, pushing Portola’s drug forward is part of a global competition with other makers of next-generation anticoagulants, including Boehringer Ingelheim and partners Bayer and Johnson & Johnson. Boehringer’s Pradaxa got a leg up on its rivals last year when the German company won FDA approval for Praxbind, an in-house reversal agent for its blood thinner.

As for Eisai, the Japanese drugmaker is working to mend its balance sheet and build out a pipeline. Thanks in part to patent expiries for Alzheimer’s drug Aricept and acid reflux treatment AcipHex, Eisai’s revenues are on the decline. And the company’s latest launches, the weight-loss drug Belviq and seizure medication Fycompa, are facing exclusivity problems of their own. The company scored a much-needed victory last year with the FDA approval of Lenvima, a treatment for thyroid cancer that Eisai believes can bring in more than $1 billion in annual sales at its peak.

By Damian Garde

Source: Fierce Biotech

comments closed

Related News

January 29, 2023

Colorcon, Inc. signs Put agreement with intent to acquire controlled atmosphere packaging specialist Airnov Healthcare Packaging

Life sciences

Airnov provides critical healthcare industries with high-quality, controlled atmosphere packaging, to protect their products from moisture and oxygen. The business has manufacturing facilities in the USA, France, China and India and employs around 700 people.

January 29, 2023

Takeda pledges up to $1.13B for rights to Hutchmed’s cancer drug fruquintinib outside of China

Life sciences

Takeda of Japan has partnered with Hong Kong-based Hutchmed, gaining the commercial rights to colorectal cancer drug fruquintinib outside of China for $400 million up front, plus $730 million in potential milestone payments. Takeda also will help develop fruquintinib, which can be applied to subtypes of refractory metastatic colorectal cancer, regardless of biomarker status, the companies said.

January 29, 2023

Vir taps Bayer dealmaker Marianne De Backer as its next CEO

Life sciences

On April 3, Scangos, who’s been chief executive officer at Vir since the start of 2017, will hand over the reins to Marianne De Backer, Ph.D. De Backer comes over from Bayer, where she currently heads up pharmaceutical strategy, business development and licensing. Alongside her CEO appointment, De Backer is set to join Vir’s board of directors, the company said Wednesday.

How can we help you?

We're easy to reach